REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.55 Billion KRW | -45.14% |
| 2022 | 8.98 Billion KRW | 14.82% |
| 2021 | 6.21 Billion KRW | 13.0% |
| 2020 | 9.04 Billion KRW | -26.56% |
| 2019 | 10.69 Billion KRW | 95.76% |
| 2018 | 4.32 Billion KRW | -65.67% |
| 2017 | 18 Billion KRW | 16.49% |
| 2016 | 16 Billion KRW | -25.86% |
| 2015 | 22.37 Billion KRW | 17.85% |
| 2014 | 16.96 Billion KRW | -11.49% |
| 2013 | 20.71 Billion KRW | -17.57% |
| 2012 | 25.11 Billion KRW | -7.65% |
| 2011 | 27.19 Billion KRW | -7.31% |
| 2010 | 29.34 Billion KRW | 22.38% |
| 2009 | 23.97 Billion KRW | 63.82% |
| 2008 | 14.63 Billion KRW | 19.02% |
| 2007 | 12.3 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.06 Billion KRW | 252.52% |
| 2024 Q2 | 385.26 Million KRW | -54.55% |
| 2023 Q4 | 2.71 Billion KRW | -85.21% |
| 2023 Q2 | 20.4 Billion KRW | -2.17% |
| 2023 Q3 | 18.33 Billion KRW | -10.13% |
| 2023 FY | - KRW | -45.14% |
| 2023 Q1 | 20.85 Billion KRW | 540.28% |
| 2022 Q4 | 3.25 Billion KRW | -18.79% |
| 2022 Q3 | 4.01 Billion KRW | 338.71% |
| 2022 Q1 | 4.04 Billion KRW | 47.26% |
| 2022 FY | - KRW | 14.82% |
| 2022 Q2 | 914.2 Million KRW | -77.4% |
| 2021 Q3 | 717.46 Million KRW | -84.55% |
| 2021 Q1 | 2.33 Billion KRW | -34.52% |
| 2021 FY | - KRW | 13.0% |
| 2021 Q2 | 4.64 Billion KRW | 98.55% |
| 2021 Q4 | 2.74 Billion KRW | 282.87% |
| 2020 Q3 | 1.82 Billion KRW | -6.37% |
| 2020 Q2 | 1.95 Billion KRW | 49.62% |
| 2020 Q1 | 1.3 Billion KRW | -67.58% |
| 2020 FY | - KRW | -26.56% |
| 2020 Q4 | 3.57 Billion KRW | 95.19% |
| 2019 Q2 | 1.99 Billion KRW | -43.75% |
| 2019 Q4 | 4.02 Billion KRW | 35.38% |
| 2019 FY | - KRW | 95.76% |
| 2019 Q1 | 3.55 Billion KRW | 236.44% |
| 2019 Q3 | 2.97 Billion KRW | 49.01% |
| 2018 Q3 | 1.92 Billion KRW | 0.8% |
| 2018 FY | - KRW | -65.67% |
| 2018 Q4 | -2.6 Billion KRW | -234.96% |
| 2018 Q2 | 1.91 Billion KRW | -60.31% |
| 2018 Q1 | 4.81 Billion KRW | 121.57% |
| 2017 FY | - KRW | 16.49% |
| 2017 Q4 | 2.17 Billion KRW | -55.57% |
| 2017 Q3 | 4.89 Billion KRW | 5.41% |
| 2017 Q2 | 4.64 Billion KRW | -29.42% |
| 2017 Q1 | 6.58 Billion KRW | 115.55% |
| 2016 Q3 | 3.21 Billion KRW | -10.01% |
| 2016 FY | - KRW | -25.86% |
| 2016 Q4 | 3.05 Billion KRW | -4.99% |
| 2016 Q2 | 3.57 Billion KRW | -37.21% |
| 2016 Q1 | 5.68 Billion KRW | -14.23% |
| 2015 Q3 | 5.19 Billion KRW | 15.67% |
| 2015 Q4 | 6.62 Billion KRW | 27.58% |
| 2015 Q2 | 4.49 Billion KRW | -14.81% |
| 2015 Q1 | 5.27 Billion KRW | 74.07% |
| 2015 FY | - KRW | 17.85% |
| 2014 Q4 | 3.02 Billion KRW | -45.63% |
| 2014 Q2 | 5.14 Billion KRW | 9.53% |
| 2014 Q1 | 4.69 Billion KRW | -7.74% |
| 2014 FY | - KRW | -11.49% |
| 2014 Q3 | 5.57 Billion KRW | 8.41% |
| 2013 Q1 | 3.77 Billion KRW | -42.22% |
| 2013 Q2 | 6.3 Billion KRW | 67.05% |
| 2013 Q4 | 5.08 Billion KRW | 0.79% |
| 2013 Q3 | 5.04 Billion KRW | -19.91% |
| 2013 FY | - KRW | -17.57% |
| 2012 FY | - KRW | -7.65% |
| 2012 Q4 | 6.52 Billion KRW | -3.45% |
| 2012 Q3 | 6.76 Billion KRW | 2.87% |
| 2012 Q2 | 6.57 Billion KRW | 45.1% |
| 2012 Q1 | 4.52 Billion KRW | -11.89% |
| 2011 Q2 | 6.33 Billion KRW | -29.96% |
| 2011 Q1 | 9.04 Billion KRW | 11.53% |
| 2011 Q3 | 6.22 Billion KRW | -1.69% |
| 2011 Q4 | 5.14 Billion KRW | -17.48% |
| 2011 FY | - KRW | -7.31% |
| 2010 Q3 | 8.37 Billion KRW | 37.55% |
| 2010 FY | - KRW | 22.38% |
| 2010 Q2 | 6.08 Billion KRW | 0.0% |
| 2010 Q4 | 8.11 Billion KRW | -3.12% |
| 2009 FY | - KRW | 63.82% |
| 2008 FY | - KRW | 19.02% |
| 2007 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -34.922% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 95.363% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 110.236% |
| HANDOK Inc. | 35.06 Billion KRW | 81.307% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 732.367% |
| Yuhan Corporation | 127.43 Billion KRW | 94.856% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 82.53% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 130.225% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 97.973% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -31.353% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 56.642% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -91.611% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -44.816% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 81.528% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -34.922% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 135.486% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 113.298% |
| JW Holdings Corporation | 187.88 Billion KRW | 96.511% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 112.796% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 97.689% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 92.653% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 117.684% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 50.377% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 44.58% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 64.862% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -34.922% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 88.076% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 96.025% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 92.653% |
| Yuhan Corporation | 127.43 Billion KRW | 94.856% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 80.419% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 14.312% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 91.49% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 92.653% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 82.107% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 90.739% |
| CKD Bio Corp. | -1.63 Billion KRW | 502.036% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 86.836% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 79.869% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 82.193% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 117.684% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 89.476% |
| Boryung Corporation | 114.28 Billion KRW | 94.265% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 121.444% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 56.642% |
| JW Lifescience Corporation | 50.82 Billion KRW | 87.104% |